Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:ARVN NASDAQ:ESPR NASDAQ:ORKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$8.20+2.5%$9.04$3.75▼$11.54$132.51M2.7187,795 shs33,875 shsARVNArvinas$7.53$7.47$5.90▼$29.61$552.85M2.382.11 million shs2.36 million shsESPREsperion Therapeutics$2.48-1.2%$2.00$0.69▼$3.94$500.02M0.895.03 million shs6.57 million shsORKAOruka Therapeutics$15.56-9.3%$14.86$5.49▼$31.13$582.72M-0.26257,603 shs543,555 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-0.25%-15.34%-1.23%-10.01%+799,999,900.00%ARVNArvinas+0.13%-2.71%+2.87%-2.71%-70.62%ESPREsperion Therapeutics-5.64%-9.71%+15.67%+134.58%+49.40%ORKAOruka Therapeutics+10.08%+12.17%+10.86%+45.55%-31.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$8.20+2.5%$9.04$3.75▼$11.54$132.51M2.7187,795 shs33,875 shsARVNArvinas$7.53$7.47$5.90▼$29.61$552.85M2.382.11 million shs2.36 million shsESPREsperion Therapeutics$2.48-1.2%$2.00$0.69▼$3.94$500.02M0.895.03 million shs6.57 million shsORKAOruka Therapeutics$15.56-9.3%$14.86$5.49▼$31.13$582.72M-0.26257,603 shs543,555 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-0.25%-15.34%-1.23%-10.01%+799,999,900.00%ARVNArvinas+0.13%-2.71%+2.87%-2.71%-70.62%ESPREsperion Therapeutics-5.64%-9.71%+15.67%+134.58%+49.40%ORKAOruka Therapeutics+10.08%+12.17%+10.86%+45.55%-31.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00143.90% UpsideARVNArvinas 2.59Moderate Buy$17.13127.51% UpsideESPREsperion Therapeutics 2.80Moderate Buy$7.00182.26% UpsideORKAOruka Therapeutics 3.20Buy$42.00169.92% UpsideCurrent Analyst Ratings BreakdownLatest ACOG, ARVN, ESPR, and ORKA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/19/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.009/18/2025ARVNArvinasWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $9.009/18/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $10.009/18/2025ARVNArvinasStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$16.00 ➝ $14.009/17/2025ARVNArvinasBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.009/17/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $56.009/16/2025ARVNArvinasBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/18/2025ORKAOruka TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.008/12/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$40.008/7/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $18.008/7/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$19.00 ➝ $16.00(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha CognitionN/AN/AN/AN/A$2.59 per shareN/AARVNArvinas$263.40M2.10N/AN/A$8.17 per share0.92ESPREsperion Therapeutics$332.31M1.50$0.02 per share110.71($1.97) per share-1.26ORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$14.64M-$1.60N/A∞N/AN/A-80.16%-60.95%11/13/2025 (Estimated)ARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)ESPREsperion Therapeutics-$51.74M-$0.49N/AN/A59.75-35.84%-0.91%-28.41%11/6/2025 (Estimated)ORKAOruka Therapeutics-$83.72M-$2.81N/AN/AN/AN/A-26.26%-24.16%11/12/2025 (Estimated)Latest ACOG, ARVN, ESPR, and ORKA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ACOGAlpha Cognition-$0.46-$0.65-$0.19-$0.65$2.32 million$1.66 million8/11/2025Q1 2025ORKAOruka Therapeutics-$0.48-$0.46+$0.02-$0.46N/AN/A8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A17.1416.83ARVNArvinasN/A5.645.64ESPREsperion TherapeuticsN/A1.150.76ORKAOruka TherapeuticsN/A27.4227.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AARVNArvinas95.19%ESPREsperion Therapeutics47.39%ORKAOruka Therapeutics56.44%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%ARVNArvinas4.73%ESPREsperion Therapeutics1.70%ORKAOruka Therapeutics24.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.16 million13.90 millionN/AARVNArvinas42073.42 million69.95 millionOptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableORKAOruka TherapeuticsN/A37.45 million28.20 millionN/AACOG, ARVN, ESPR, and ORKA HeadlinesRecent News About These CompaniesQ3 EPS Estimates for Oruka Therapeutics Increased by WedbushSeptember 23 at 2:11 AM | americanbankingnews.comQ3 EPS Forecast for Oruka Therapeutics Increased by AnalystSeptember 22 at 2:14 AM | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Trading Down 6.2% - Here's What HappenedSeptember 20 at 5:21 PM | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street ZenSeptember 20 at 2:08 AM | marketbeat.comOruka Therapeutics, Up 10%, Is Trying To Take On AbbVie's Biggest MoneymakerSeptember 19, 2025 | msn.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Expected to Rise, BTIG Research Analyst SaysSeptember 19, 2025 | marketbeat.comOruka Therapeutics presents positive interim phase 1 results for ORKA-001 at EADV CongressSeptember 18, 2025 | pharmabiz.comPOruka Therapeutics (NASDAQ:ORKA) Shares Gap Up - Still a Buy?September 18, 2025 | marketbeat.comOruka reveals $180M financing and late breaking psoriasis dataSeptember 18, 2025 | thepharmaletter.comTOruka Therapeutics stock surges after positive Phase 1 resultsSeptember 18, 2025 | za.investing.comOruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trialSeptember 18, 2025 | msn.comOruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest MoneymakerSeptember 18, 2025 | msn.comOruka Therapeutics Stock (ORKA) Soars on New Psoriasis Drug That Could Challenge AbbVie (ABBV)September 18, 2025 | msn.comOruka Therapeutics Secures $180 Million in PIPE Financing to Advance Chronic Skin Disease TreatmentsSeptember 17, 2025 | quiverquant.comQOruka Therapeutics Announces $180 Million Private PlacementSeptember 17, 2025 | globenewswire.comOruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001September 17, 2025 | globenewswire.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Down 5.4% - Here's What HappenedSeptember 14, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Has $461,000 Holdings in Oruka Therapeutics, Inc. $ORKASeptember 5, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Shares Up 6.6% - Time to Buy?September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases Shares of 132,780 Oruka Therapeutics, Inc. $ORKASeptember 4, 2025 | marketbeat.comRedmile Group LLC Cuts Position in Oruka Therapeutics, Inc. $ORKASeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACOG, ARVN, ESPR, and ORKA Company DescriptionsAlpha Cognition NASDAQ:ACOG$8.20 +0.20 (+2.50%) As of 04:00 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Arvinas NASDAQ:ARVN$7.53 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$7.52 -0.01 (-0.13%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Esperion Therapeutics NASDAQ:ESPR$2.48 -0.03 (-1.20%) Closing price 04:00 PM EasternExtended Trading$2.48 0.00 (-0.20%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Oruka Therapeutics NASDAQ:ORKA$15.56 -1.59 (-9.27%) Closing price 04:00 PM EasternExtended Trading$15.84 +0.28 (+1.80%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
